Arena Pharmaceuticals (ARNA) Beats On Q4 Earnings & Revenues
Zacks Investment Research | Feb 26, 2019 08:25PM ET
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported earnings of $1.35 per share in the fourth quarter of 2018, which surpassed the Zacks Consensus Estimate of a loss of 76 cents. The bottom line also improved from a loss of 35 cents incurred in the year-ago period.
Total revenues came in at $8.6 million, down 43.7% from the year-earlier period. However, the top line outpaced the Zacks Consensus Estimate of $3.43 million. Revenues comprised $1.8 million as royalty revenues and $6.9 million as collaboration revenues.
Shares of Arena increased 2.3% in pre-market trading on Feb 26, presumably on better-than-expected results. Moreover, the stock has gained 29.9% in the past year.
Research & development (R&D) expenses soared 82.9% from the prior-year level to $37.9 million.
General and administrative expenses surged 86.6% from the year-ago level to $15.4 million.
Full-Year Results
Arena reported total revenues of $18 million in 2018, down 15.8% on a year-over-year basis. However, loss per share narrowed to 63 cents compared with $2.77 in the year-ago period.
Restructuring Update
In January, Arena closed a deal with United Therapeutics (NASDAQ:UTHR) out-licensing global rights to ralinepag — its late-stage candidate for the treatment of pulmonary arterial hypertension (“PAH”). United Therapeutics is now responsible for further development and commercializing the candidate.
Per the terms of the deal, Arena is eligible to receive up to $1.2 billion including an upfront payment of $800 million, potential milestone up to $400 million and tiered low double-digit royalties on the net sales of ralinepag from United Therapeutics.
Pipeline Update
Arena’s pipeline currently consists of two key candidates, namely etrasimod (autoimmune diseases) and Olorinab (pain and fibrotic diseases).
Etrasimod, a once-daily oral sphingosine-1-phosphate (S1P) modulator, is being developed for the treatment of Ulcerative colitis (“UC”), Crohn's disease (“CD”) and Atopic dermatitis (“AD”). While a late-stage study on UC is being planned following positive data from the phase II OASIS study, two separate mid-stage studies are expected to start soon for treating CD and AD.
Olorinab, a cannabinoid 2 (CB2) receptor agonist, is being developed for treating visceral pain associated with gastrointestinal disease. A phase IIb is being planned to evaluate the candidate for treating the indication.
Apart from these two candidates, Arena plans to launch APD418 — a first-in-class calcium-independent myofilament derepressor ("CMD") — which is in preclinical studies for the treatment of decompensated heart failure. The company plans to move the candidate into clinical studies in 2019.
Zacks Rank & Key Picks
Arena currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the healthcare sector include Celgene Corporation (NASDAQ:CELG) and Genomic Health, Inc. (NASDAQ:GHDX) , each sporting a Zacks Rank #1 (Strong Buy). You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.